Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/trf.15910 http://scihub22266oqcxt.onion/10.1111/trf.15910 32449169!7283779!32449169     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Transfusion 2020 ; 60 (7): 1348-1355 Nephropedia Template TP {{tp|p=32449169|t=2020. How did we rapidly implement a convalescent plasma program?|pdf=|usr=}}{{32449169}} gab.com Text How did we rapidly implement a convalescent plasma program JO: Transfusion http://www.kidney.de/pget.php?&tw=1&pmid=32449169 #FOAvip Since the beginning of the COVID-19 pandemic, the use of convalescent plasma as a possible treatment has been explored. Here we describe our experience as the first U.S. organization creating a COVID-19 convalescent plasma program to support its use through the single-patient emergency investigational new drug, the National Expanded Access Program, and multiple randomized controlled trials. Within weeks, we were able to distribute more than 8000 products, scale up collections to more than 4000 units per week, meet hospital demand, and support randomized controlled trials to evaluate the efficacy of convalescent plasma treatment. This was through strategic planning; redeployment of staff; and active engagement of hospital, community, and public health partners. Our partners helped with donor recruitment, testing, patient advocacy, and patient availability. The program will continue to evolve as we learn more about optimizing the product. Remaining issues to be resolved are antibody titers, dose, and at what stage of disease to transfuse. Twit Text FOAVip How did we rapidly implement a convalescent plasma program ????Transfusion http://www.kidney.de/pget.php?&tw=1&pmid=32449169 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32449169 #FOAvip English Wikipedia <ref>{{Cite pmid|32449169}}</ref> How did we rapidly implement a convalescent plasma program? #MMPMID32449169 Budhai A; Wu AA; Hall L; Strauss D; Paradiso S; Alberigo J; Hillyer CD; Jett B; Tobian AAR; Bloch EM; Sachais BS; Shaz BH Transfusion 2020[Jul]; 60 (7): 1348-1355 PMID32449169show ga Since the beginning of the COVID-19 pandemic, the use of convalescent plasma as a possible treatment has been explored. Here we describe our experience as the first U.S. organization creating a COVID-19 convalescent plasma program to support its use through the single-patient emergency investigational new drug, the National Expanded Access Program, and multiple randomized controlled trials. Within weeks, we were able to distribute more than 8000 products, scale up collections to more than 4000 units per week, meet hospital demand, and support randomized controlled trials to evaluate the efficacy of convalescent plasma treatment. This was through strategic planning; redeployment of staff; and active engagement of hospital, community, and public health partners. Our partners helped with donor recruitment, testing, patient advocacy, and patient availability. The program will continue to evolve as we learn more about optimizing the product. Remaining issues to be resolved are antibody titers, dose, and at what stage of disease to transfuse. |*Antibodies, Viral/blood/therapeutic use[MESH] |*Betacoronavirus[MESH] |*Blood Component Transfusion[MESH] |*Coronavirus Infections/blood/epidemiology/therapy[MESH] |*Pandemics[MESH] |*Plasma[MESH] |*Pneumonia, Viral/blood/epidemiology/therapy[MESH] |COVID-19[MESH] |COVID-19 Serotherapy[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Randomized Controlled Trials as Topic[MESH]How did we rapidly implement a convalescent plasma program?(epmc).pdf DeepDyve Pubget Overpricing